Nomura initiates Anthem Biosciences stock with Buy rating on growth outlook

Nomura/Instinet initiated coverage of Anthem Biosciences with a Buy rating and a INR740 price target, valuing the stock at 50x December 2027 forecast EPS of INR14.8. The firm projects revenue growth of 14%, 18% and 22% for fiscal 2026–2028 and earnings growth of 27%, 21% and 26% over the same period, citing sustained base-product performance and new launches as drivers. Nomura justifies a premium multiple based on high profitability, execution and disciplined capital allocation, while flagging concentration risk with the top two products expected to account for 36%–38% of revenue in 2026–2028.

Analysis

Market structure: Nomura’s Buy and 50x Dec-2027 EPS-based PT (INR740) signals a growth-premium flowing into Indian specialty/biotech midcaps, benefiting ANTHEM:IN, its contract manufacturers and API suppliers. Losers are lower-margin generics and broad pharma ETFs as capital reallocates to high-ROIC, high-visibility names; a 20-30% rerating gap versus peers is possible if execution continues. Cross-asset: outperforming equity flows into ANTHEM can tighten IG credit spreads in the sector, push INR slightly firmer on FPI flows, and lift implied vols — expect 15-30% IV re-pricing around earnings/approvals.

Risk assessment: Key tail risks are product-specific regulatory action, patent/label setbacks, or a manufacturing stoppage — a 20% decline in top product sales would shave ~7–8% off total revenue given the 36–38% concentration. Near term (days–weeks) expect volatility around research notes and launch updates; short-term (3–6 months) depends on first new-launch cadence; long-term (FY27–28) execution risk on sustaining 18–22% revenue growth is critical. Hidden dependencies include API sourcing from China (FX/supply shocks) and distributor concentration; catalysts that could flip the story are a new label approval or an adverse inspection within 30–90 days.

Trade implications: Direct play — selectively long ANTHEM:IN sized 2–3% of portfolio, scaled over 4 weeks to avoid front-running the initiation move, with a hard stop at −20% or if FY26 guidance is cut >5%. Options — buy a 9–12 month call spread (buy ATM, sell 25% OTM) sized 0.5–1% to capture upside while limiting Vega cost ahead of approval/earnings windows. Pair trade — long ANTHEM 2% vs short SUNPHARMA.NS 2% to isolate idiosyncratic upside while hedging sector beta; rebalance monthly.

Contrarian angles: Consensus underweights the concentration risk; that risk is binary — historical parallels (single-product hits in midcaps) show 30–50% downside on adverse events, so downside is underpriced if implied vol is low. Conversely, consensus may also under-appreciate upside from successful FY27 launches: a 15–25% beat in FY27 EPS could re-rate ANTHEM another 20–40% given the 50x multiple. Unintended consequences: the high multiple invites competition and regulatory scrutiny—if the top-two product share rises above 40% or API costs jump 15% YoY, the trade reverses quickly.

Key Decisions for Investors

• Establish a 2–3% portfolio long in ANTHEM:IN over 2–4 weeks (scale in 25% tranches); target price INR740 by Dec 2027; implement a stop-loss at −20% absolute or exit 50% of position if FY26 guidance is reduced by >5% (measured at next quarterly release).
• Buy a 9–12 month call spread on ANTHEM:IN (buy ATM call, sell 25% OTM call) sized 0.5–1% of portfolio to express bullish view with defined risk; roll or unwind after any major approval/earnings within 30–90 days if implied vol compresses >10 vols.
• Pair trade: go long ANTHEM:IN 2% and short SUNPHARMA.NS 2% to hedge sector beta and isolate idiosyncratic execution risk; rebalance monthly and tighten pair if ANTHEM’s top-two products exceed 40% revenue share or fall >15% QoQ.
• Reduce exposure by 50% to undiversified Indian midcap pharma names where PE >30x and top‑two product concentration >30% within 30 days; redeploy proceeds into diversified large-cap pharma or targeted biotech winners with lower concentration risk.